Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome.
about
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts--from the point of view of mouse genomics.An update on autoinflammatory diseasesPeriodic Fever and Neutrophilic Dermatosis: Is It Sweet's Syndrome?An expanding role for interleukin-1 blockade from gout to cancer.[Sweet Syndrome: Clinical and pathologic study over 5 years].Schnitzler's disease as an important differential diagnosis of chronic recurrent multifocal osteomyelitis: a case report.Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A French Multicenter Study of 17 Cases and Literature ReviewAnti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Nodular kidney involvement in a patient with idiopathic Sweet's syndrome.Treating inflammation by blocking interleukin-1 in humans.Sweet's syndrome with idiopathic thrombocythemia.A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood.The continuing evolution of targeted therapy for inflammatory skin disease.Drug management of neutrophilic dermatoses.Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report.Inflammasomes and dermatology.Are neutrophilic dermatoses autoinflammatory disorders?Refractory Sweet's syndrome successfully treated with rituximab.Sweet's Syndrome Successfully Treated with Granulocyte and Monocyte Adsorption Apheresis.Sweet Syndrome: Clinical Features, Histopathology, and Associations of 83 Cases.DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?IL-1 Inhibition in Cryopyrin-Associated Periodic Syndrome and Beyond: A Million Dollar Question about the Injection Schedule of BiotherapiesAnakinra Therapy for Non-cancer Inflammatory Diseases
P2860
Q33710807-76E1583C-FF39-4EF9-9E0A-AA7383BA31F4Q34081473-FD6CF621-5209-4FB9-885D-28030544D5D6Q34380526-193ADA25-D1EF-47D7-AF8E-99D9F111D14EQ34754365-DCDD44CD-BBDA-4C95-8727-12EFD6F0F9A6Q35219001-B306A31F-18ED-4F48-84D2-6E54FE86121BQ35831184-FCA41516-140A-48C5-9823-C72F88F3A1CEQ36171132-328421A3-9701-4CAA-A83A-3F62FAD6919AQ36822636-55762615-2A59-49F1-BB48-C165C380A4C4Q36990716-2C1730A2-F8AF-4589-B6C8-672C15DC34E5Q37270409-AF24A38B-5AE9-4C95-BCF0-DA1ED345F347Q37391987-09CF7CFD-92C0-4B67-9B69-6358E8C731F7Q37636664-C4E7CBF7-8A65-42A0-AF37-1FA9CCDE1104Q38262390-5BF4A585-7125-4A62-80C5-3309FEEB602AQ38366349-26ECCF0B-CBD8-43F2-8B97-A4BC915BECE8Q38596134-335D11A5-DB6C-4E58-8610-67DBB0BD23B1Q38656412-B68A6627-E808-42A2-ADD7-9DCB5107C27EQ38721101-9649DE1B-3497-4F16-978C-A220B512AF22Q38797090-A7993160-7E2E-4549-8B36-AEE851845B54Q39025288-CDBA52BC-EEA6-4949-9B09-C4145BFABE95Q39534447-E3EB4657-7AD3-45DC-A1BC-5B635EBC74A2Q40052767-65E0F135-66C8-445F-9D4B-D7EF9C8589F3Q40065003-177FF346-46C7-4072-83D4-41A49DFD8669Q42505905-D053AD98-782B-4841-97A6-B82530009648Q58853108-901D424A-505B-4D47-BF43-0D034C194A29Q59136398-BC63699B-4C6B-4D13-B780-95E632F8BC27
P2860
Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Efficacy of anti-interleukin-1 ...... f refractory Sweet's syndrome.
@en
type
label
Efficacy of anti-interleukin-1 ...... f refractory Sweet's syndrome.
@en
prefLabel
Efficacy of anti-interleukin-1 ...... f refractory Sweet's syndrome.
@en
P2093
P2860
P356
P1433
P1476
Efficacy of anti-interleukin-1 ...... f refractory Sweet's syndrome.
@en
P2093
Bernard Guillot
Didier Bessis
Déborah Gil-Bistes
Nicolas Kluger
P2860
P304
P356
10.1159/000326112
P577
2011-04-05T00:00:00Z